For CFOs wanting to understand investor behavior, here's an argument that Jeff Bezos is human, after all, and Amazon can't defy basic economic principles.
A federal official says the drugmaker misclassified EpiPen, possibly costing Medicaid millions of dollars in rebates.
The acquisition of Afferent Pharmaceuticals gives Merck access to a drug candidate for treating neurogenic conditions including chronic cough.
If Anacor's treatment for eczema is approved by the FDA, Pfizer predicts peak-year sales could exceed $2 billion.
The ex-CFO of Aveo Pharmaceuticals and other top executives allegedly failed to disclose FDA concerns about an experimental cancer drug.
The drug maker says the deal will further its goal of "building the leading biotechnology company focused on rare diseases."
Michael Pearson, who was hospitalized with pneumonia, has been trying to win back investor trust amid concerns over Valeant's pricing practices.
The Swiss drug maker allegedly turned specialty pharmacies into a "biased sales force" for its medications.
The deal gives the acquisitive Irish company access to an experimental drug that competes with its own treatment for a rare disease.
The acquisitions give the Indian drug maker its first manufacturing plant in the U.S. and an opportunity to build U.S. market share.
If the deal is approved, Teva says the combined company would have revenue of about $26 billion and EBITDA of $9.5 billion in 2016.
